title: Neurotoxic effects of methamphetamine.
abstract: In Parkinson's disease, depletion of dopamine in the striatum leads to various symptoms such as tremor, rigidity and akinesia. Methamphetamine use has significantly increased in USA and around the world and there are several reports showing that its long-term use increases the risk for dopamine depletion. However, the toxic mechanisms of methamphetamine are not well understood. This study was undertaken to gain greater mechanistic understanding of the toxicity induced by methamphetamine. We evaluated the effect of methamphetamine on the generation of reactive oxygen species, mitochondrial monoamine oxidase, complex I & IV activities. Behavioral analysis evaluated the effect on catalepsy, akinesia and swim score. Neurotransmitter levels were evaluated using high pressure liquid chromatography (HPLC) electrochemical detection (ECD). Results showed that methamphetamine caused significant generation of reactive oxygen species and decreased complex I activity in the mitochondria leading to dopamine depletion in the striatum.
authors.affiliation: Department of Pharmacal Sciences, Harrison School of Pharmacy, Auburn University, 4306 Walker building, Auburn, AL 36849, USA.
authors.forename: Bessy
authors.initials: B
authors.lastname: Thrash
authors.forename: Senthilkumar S
authors.initials: SS
authors.lastname: Karuppagounder
authors.forename: Subramaniam
authors.initials: S
authors.lastname: Uthayathas
authors.forename: Vishnu
authors.initials: V
authors.lastname: Suppiramaniam
authors.forename: Muralikrishnan
authors.initials: M
authors.lastname: Dhanasekaran
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism / Q000502:physiology; D004563:Electrochemistry; D008297:Male; D008694:Methamphetamine / Q000633:toxicity*; D051379:Mice; D008810:Mice, Inbred C57BL; D008995:Monoamine Oxidase / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D013378:Substantia Nigra / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism / Q000502:physiology
chemical_list: D017382:Reactive Oxygen Species; D008694:Methamphetamine; D008995:Monoamine Oxidase
references.citation: Science. 2003 Oct 31;302(5646):819-22
references.pmid: 14593166
references.citation: Biochem Biophys Res Commun. 1986 Feb 26;135(1):269-75
references.pmid: 3485428
references.citation: J Pharmacol Exp Ther. 2009 Jul;330(1):316-25
references.pmid: 19364908
references.citation: J Pharmacol Exp Ther. 1998 Oct;287(1):107-14
references.pmid: 9765328
references.citation: J Neurol Neurosurg Psychiatry. 1994 Jun;57(6):672-81
references.pmid: 7755681
references.citation: Ann N Y Acad Sci. 2000 Sep;914:146-56
references.pmid: 11085317
references.citation: Exp Neurol. 2003 Jan;179(1):9-16
references.pmid: 12504863
references.citation: Neurosci Lett. 1995 Jun 23;193(1):53-6
references.pmid: 7566666
references.citation: Eur J Pharmacol. 2000 Jul 14;400(1):99-102
references.pmid: 10913590
references.citation: FASEB J. 2003 Oct;17(13):1775-88
references.pmid: 14519657
references.citation: J Pharmacol Exp Ther. 2004 Oct;311(1):1-7
references.pmid: 15163680
references.citation: Neuroscience. 1996 Jun;72(3):593-600
references.pmid: 8861054
references.citation: Fed Proc. 1973 Feb;32(2):183-90
references.pmid: 4143953
references.citation: Mov Disord. 1998;13 Suppl 1:24-34
references.pmid: 9613715
references.citation: Brain Res. 2001 Feb 23;892(2):241-7
references.pmid: 11172770
references.citation: Toxicol Appl Pharmacol. 2005 Apr 1;204(1):57-68
references.pmid: 15781294
references.citation: Eur J Pharmacol. 1971 Oct;16(2):176-80
references.pmid: 4405780
references.citation: J Neuroendocrinol. 2001 Jul;13(7):618-24
references.pmid: 11442776
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 1997 Jul;21(5):873-83
references.pmid: 9278957
references.citation: Neuropharmacology. 1988 Oct;27(10):1077-80
references.pmid: 3237316
references.citation: Nat Med. 1996 Jun;2(6):699-703
references.pmid: 8640565
references.citation: Toxicol Lett. 2000 Dec 20;118(1-2):43-6
references.pmid: 11137307
references.citation: FASEB J. 1998 Jul;12(10):905-12
references.pmid: 9657530
references.citation: Neurosci Lett. 1988 Feb 15;85(1):137-42
references.pmid: 3258974
references.citation: Br J Exp Pathol. 1989 Dec;70(6):737-57
references.pmid: 2557883
references.citation: Lancet. 1983 Dec 24-31;2(8365-66):1457-9
references.pmid: 6140548
references.citation: J Pharmacol Sci. 2003 Jul;92(3):178-95
references.pmid: 12890883
references.citation: Eur J Pharmacol. 2000 Jun 9;398(1):11-8
references.pmid: 10856443
references.citation: AAPS J. 2006;8(2):E413-8
references.pmid: 16808044
references.citation: Ann Neurol. 1992 Dec;32(6):804-12
references.pmid: 1471873
references.citation: Brain Res Brain Res Rev. 2001 Aug;36(1):1-22
references.pmid: 11516769
references.citation: Exp Neurol. 2004 May;187(1):47-57
references.pmid: 15081587
references.citation: J Neurosci Res. 1999 Mar 15;55(6):659-65
references.pmid: 10220107
references.citation: Life Sci. 2007 Sep 1;81(12):988-92
references.pmid: 17825848
references.citation: Neuroscience. 2006 Jun 30;140(2):607-22
references.pmid: 16650608
references.citation: J Pharmacol Exp Ther. 1993 Apr;265(1):392-400
references.pmid: 8474021
references.citation: J Neurochem. 2001 Oct;79(1):152-60
references.pmid: 11595767
references.citation: Pharmacol Ther. 2005 Jul;107(1):120-30
references.pmid: 15963354
references.citation: Phytother Res. 2008 Jan;22(1):6-11
references.pmid: 18064727
references.citation: J Toxicol Clin Toxicol. 2000;38(2):123-8
references.pmid: 10778908
references.citation: J Neurol Sci. 1987 Feb;77(2-3):185-91
references.pmid: 3493329
references.citation: Ann N Y Acad Sci. 2001 Jun;939:366-80
references.pmid: 11462792